Intriguingly, vemurafenib treatment of BRAF-mutant thyroid cancer cell lines induced translocation of Yap to the nucleus and activation of its transcriptional output, which included key effectors in the NRG1 signaling pathway. The gene discussed is YAP1; the disease is thyroid gland carcinoma.